Baricitinib

巴瑞替尼

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameBaricitinib
Drug Alias Name巴西替尼Baricitinibum巴瑞克替尼Olumiant艾乐明 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Aicardi Goutieres syndromePost-Acute COVID-19 Syndrome +[46] 
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryEU
Original Approved Date2017/02/13
Country/TerritoryCzechiaBelgiumCanada +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesSt. Vincent'S Institute Of Medical ResearchGenuine Research Center, EgyptOregon Health And Science University +[30] 
Inactive CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Incepta Pharmaceuticals LtdCatalent Pharma Solutions +[10] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Aicardi Goutieres syndromePost-Acute COVID-19 Syndrome +[35] 
Inactive IndicationsPsoriasisSkin Diseases, PapulosquamousDiabetic Nephropathies +[11] 

Other Information

ATC CodeL04AF02
Related LinksWikipediaDrugBankKEGG